Table 1.
Treatment(s) | Other factor(s) | Study design and finding(s) |
---|---|---|
Tucatinib [65] | – |
To determine the MTD, antitumor activity, and pharmacokinetic properties of tucatinib The tucatinib MTD was determined to be 600 mg twice daily; 22% of patients treated at the MTD had a partial response + SD |
Tucatinib + trastuzumab + capecitabine [33] | ALT/AST |
To evaluate the therapeutic responses of tucatinib vs. placebo combination with trastuzumab and capecitabine Tucatinib-combination resulted in improved PFS and increased OS with common adverse events compared to the placebo-combination group |
HER2+ HER2-positive, MTD maximum tolerable dose, SD stable disease, ALT alanine aminotransferase, AST aspartate aminotransferase, PFS progression-free survival, OS overall survival